Depomed Company Profile (NASDAQ:DEPO)

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:DEPO
  • CUSIP: 24990810
  • Web: www.depomedinc.com
Capitalization:
  • Market Cap: $324.39 million
  • Outstanding Shares: 62,988,000
Average Prices:
  • 50 Day Moving Avg: $5.98
  • 200 Day Moving Avg: $9.25
  • 52 Week Range: $4.93 - $24.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.73
  • P/E Growth: 0.45
Sales & Book Value:
  • Annual Revenue: $425.34 million
  • Price / Sales: 0.75
  • Book Value: $3.36 per share
  • Price / Book: 1.51
Profitability:
  • EBITDA: $112.64 million
  • Net Margins: -26.02%
  • Return on Equity: -45.03%
  • Return on Assets: -9.34%
Debt:
  • Debt-to-Equity Ratio: 2.71%
  • Current Ratio: 0.79%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 1.73 million shs.
  • Beta: 1.19
  • Short Ratio: 8.72
 

Frequently Asked Questions for Depomed (NASDAQ:DEPO)

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) announced its earnings results on Monday, August, 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.52. The firm earned $100 million during the quarter, compared to analyst estimates of $100.40 million. Depomed had a negative net margin of 26.02% and a negative return on equity of 45.03%. The firm's revenue for the quarter was down 14.3% compared to the same quarter last year. During the same period last year, the company earned $0.27 earnings per share. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

9 equities research analysts have issued 12-month price objectives for Depomed's shares. Their predictions range from $5.00 to $24.00. On average, they expect Depomed's stock price to reach $12.67 in the next twelve months. View Analyst Ratings for Depomed.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board
  • Arthur J. Higgins, President, Chief Executive Officer, Director
  • August J. Moretti, Chief Financial Officer, Senior Vice President
  • Matthew M. Gosling, Senior Vice President, General Counsel
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
  • Karen A. Dawes, Independent Director
  • Louis J. Lavigne Jr., Independent Director
  • William T. McKee CPA, Independent Director
  • Gavin T. Molinelli, Independent Director

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $5.06.


MarketBeat Community Rating for Depomed (NASDAQ DEPO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $12.67 (150.33% upside)
Consensus Price Target History for Depomed (NASDAQ:DEPO)
Price Target History for Depomed (NASDAQ:DEPO)
Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/15/2017Piper Jaffray CompaniesSet Price TargetHold$9.00N/AView Rating Details
10/13/2017MizuhoReiterated RatingNeutral$11.00 -> $6.00N/AView Rating Details
8/8/2017Morgan StanleyDowngradeEqual Weight -> Underweight$12.00 -> $5.00HighView Rating Details
8/8/2017Royal Bank Of CanadaLower Price TargetSector Perform -> Sector Perform$13.00 -> $10.00HighView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy -> Neutral$18.00 -> $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Depomed (NASDAQ:DEPO)
Earnings by Quarter for Depomed (NASDAQ:DEPO)
Earnings History by Quarter for Depomed (NASDAQ DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.12N/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 91.25%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
Source:
DateHeadline
finance.yahoo.com logoDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - October 17 at 4:38 AM
feeds.benzinga.com logoEQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses Exceeding $500,000 to Contact the Firm
feeds.benzinga.com - October 16 at 9:14 PM
finance.yahoo.com logoDEPO DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - October 16 at 6:34 PM
finance.yahoo.com logoGlancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Depomed, Inc. (DEPO)
finance.yahoo.com - October 16 at 6:34 PM
finance.yahoo.com logoDEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 16 at 6:34 PM
finance.yahoo.com logoDEPO FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Depomed, Inc. (DEPO) & Lead Plaintiff Deadline: October 17, 2017
finance.yahoo.com - October 16 at 6:34 PM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 – DEPO
finance.yahoo.com - October 16 at 6:34 PM
prnewswire.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. - DEPO - PR Newswire (press release)
www.prnewswire.com - October 14 at 4:29 AM
americanbankingnews.com logoDepomed, Inc. (DEPO) Rating Reiterated by Mizuho
www.americanbankingnews.com - October 14 at 12:36 AM
finance.yahoo.com logoDEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 13 at 11:26 PM
finance.yahoo.com logoReminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Depomed, Inc. (DEPO)
finance.yahoo.com - October 13 at 6:22 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:22 PM
finance.yahoo.com logoValeant: A Problem…Or Just More Noise?
finance.yahoo.com - October 13 at 6:22 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. - DEPO
finance.yahoo.com - October 13 at 6:22 PM
globenewswire.com logoOCTOBER 17 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 6:38 PM
feeds.benzinga.com logoOCTOBER 17 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - October 12 at 3:15 PM
streetinsider.com logoDepoMed Inc (DEPO) PT Lowered to $6 at Mizuho Securities - StreetInsider.com
www.streetinsider.com - October 12 at 12:23 AM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 11 at 7:21 PM
News IconBRIEF-Depomed ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER
www.businessinsider.com - October 11 at 1:38 AM
finance.yahoo.com logoDepomed Provides Product Supply Information Following Hurricane Maria
finance.yahoo.com - October 11 at 1:38 AM
globenewswire.com logoDepomed Provides Product Supply Information Following Hurricane Maria - GlobeNewswire (press release)
globenewswire.com - October 10 at 3:34 PM
finance.yahoo.com logoONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 10 at 3:34 PM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 9 at 6:14 PM
americanbankingnews.com logoDepomed, Inc. (DEPO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 7 at 10:44 PM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - October 4 at 4:30 PM
finance.yahoo.com logoDEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 4 at 4:30 PM
finance.yahoo.com logoDEPO EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - October 3 at 5:42 PM
finance.yahoo.com logoDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 3 at 5:42 PM
finance.yahoo.com logoCan Depomed Inc (DEPO) Improve Your Portfolio Returns?
finance.yahoo.com - October 3 at 7:50 AM
finance.yahoo.com logoDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 3 at 7:50 AM
nasdaq.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
www.nasdaq.com - September 30 at 8:47 PM
globenewswire.com logoDEPO LOSS NOTICE: Rosen Law Firm Reminds Depomed, Inc. Investors of Important Deadline in Class Action – DEPO - GlobeNewswire (press release)
globenewswire.com - September 30 at 6:41 AM
feeds.benzinga.com logoDEPO LOSS NOTICE: Rosen Law Firm Reminds Depomed, Inc. Investors of Important Deadline in Class Action – DEPO
feeds.benzinga.com - September 29 at 11:22 AM
thestreet.com logoFaruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Depomed, Inc.
www.thestreet.com - September 27 at 6:44 PM
businesswire.com logoBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Depomed, Inc. (DEPO) and Encourages Investors to Contact the Firm
www.businesswire.com - September 27 at 6:44 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 25 at 4:19 PM
finance.yahoo.com logoLawsuit for Investors in Depomed Inc. (NASDAQ: DEPO) Shares Announced by Shareholders Foundation
finance.yahoo.com - September 25 at 4:19 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:19 PM
prnewswire.com logoScott+Scott, Attorneys at Law, LLP Reminds Investors of October ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 4:53 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:53 PM
finance.yahoo.com logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 5:53 PM
finance.yahoo.com logoScott+Scott, Attorneys at Law, LLP Reminds Investors of October 17th Lead Plaintiff Deadline in Securities Class Action Against Depomed, Inc. (DEPO)
finance.yahoo.com - September 21 at 5:53 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 21 at 5:53 PM
prnewswire.com logoDEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages ... - PR Newswire (press release)
www.prnewswire.com - September 20 at 11:47 PM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - September 20 at 6:46 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 20 at 6:45 PM
thestreet.com logoRelative Strength Alert For Depomed
www.thestreet.com - September 19 at 5:48 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 19 at 5:48 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Depomed, Inc. (Nasdaq: DEPO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - September 19 at 5:48 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 19 at 5:48 PM

Social

Chart

Depomed (DEPO) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.